6 January 2025
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Result of General Meeting and change of name
The board of Graft Polymer (LON:GPL), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that the resolution proposed, to enable the Company to change its name, was duly passed on a show of hands at the general meeting (the "GM") held earlier today. The results of the proxy votes received ahead of the meeting are set out below.
| Resolution | Votes for* | % | Votes against | % | Votes total | Votes withheld** |
| Resolution 1 | 754,271,622 | 99.53 | 3,565,847 | 0.47% | 757,837,469 | 0 |
* Includes discretionary votes
**A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" any of the resolutions
Change of name
Having received shareholder approval at the GM, the Company's name will be changed to Solvonis Therapeutics plc. The relevant paperwork will be filed with Companies House shortly, and a further announcement will be made when the name change is formally effective. Upon the change of name becoming effective, the Company's TIDM will change from "GPL" to "SVNS".
The ISIN and SEDOL numbers for the Company's ordinary shares will remain unchanged as GB00BMD1Z199 and BMD1Z19 respectively.
Shareholders are unaffected by the changes and existing share certificates will remain valid and should be retained.
For more information, please visit www.graftpolymer.co.uk.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. anthonytennyson@graftpolymer.co.uk
Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU markets.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
